CPA
ANRO icon

Capital Performance Advisors’s Alto Neuroscience ANRO Stock Holding History

Capital Performance Advisors’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4
Closed -$46 – 2779
2024
Q3 		$46 Buy
+4
New +$49 ﹤0.01% 2799

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capital Performance Advisors's ANRO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Alto Neuroscience (ANRO) in Q4 2024, closing a stake of 4 shares — an estimated $46 sold.

Capital Performance Advisors first reported a position in ANRO in Q3 2024 and held it in 1 quarter. The position peaked at $46 in Q3 2024. 77 funds tracked by Wall St. Rank hold ANRO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Alto Neuroscience position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 4 Alto Neuroscience shares in Q4 2024, an estimated $46.
  • Capital Performance Advisors first reported a position in Alto Neuroscience in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Alto Neuroscience position peaked at $46 in Q3 2024.
  • 77 funds tracked by Wall St. Rank held Alto Neuroscience as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.